AltruBio
AltruBio develops first-in-class immune-modulators for immunological and inflammatory diseases. Its lead antibody, ALTB-268, targets patients with Ulcerative Colitis.
Secondary Market Price
How AltruBio Measures Up
To help you manage your AltruBio equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series B
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of AltruBio's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future AltruBio Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for AltruBio's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
AltruBio is a biopharmaceutical company developing antibody therapeutics for immunological and inflammatory diseases, as well as for cancer. The company's lead program is ALTB-268, an immune checkpoint agonist antibody being developed for Ulcerative Colitis (UC), which is currently in a Phase 2a clinical trial. Its product pipeline also includes a gastrointestinal tumor-selective antigen and a linker for antibody-drug conjugate products. Originally founded as AbGenomics in 2006, the company later became AltruBio and has raised a total of $39.7 million in funding.
Looking forward, AltruBio is focused on completing enrollment for its Phase 2a trial for ALTB-268 and is actively engaging with potential investors and partners to accelerate the drug's development. Recent company activity has centered on its leadership's participation in major industry events. The company's CEO, Dr. Judy Chou, has presented advancements on ALTB-268 at the Piper Sandler and Stifel Healthcare Conferences and is scheduled to speak at Fierce Biotech Week and the APEC CEO Summit in 2025. In 2025, Dr. Chou was also recognized by Endpoints News as one of the top 20 visionary women in biopharma.
- BVF Partners LP
- RA Capital Management
- Cormorant Asset Management
- Soleus Capital
- aMoon Fund
- Blackstone Multi-Asset Investing
- Delos Capital
- Co-Founder, Rong-Hwa Lin
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is AltruBio worth joining?
Evaluating an offer from a startup like AltruBio involves assessing the company's potential and the value of its equity compensation package. Tools like Prospect can help you forecast the potential future value of your stock options or RSUs to make a more data-driven decision.
What should I do with my AltruBio stock?
The right strategy for your private stock depends on your personal financial goals, risk tolerance, and the potential tax implications of any action. A platform like Prospect can help you model different scenarios, such as exercising options or selling shares, to determine the optimal path for your situation.
Can you sell AltruBio stock?
As a private company, AltruBio stock is not publicly traded, but employees can often sell shares through company-approved tender offers or on secondary markets. Prospect's tools can help you navigate these events by determining how much to sell and which shares are the most tax-efficient to offload.
How can I find the value of my AltruBio stock?
Determining the value of private stock can be difficult due to the lack of public market data, but specialized platforms can provide data-driven estimates. Prospect uses predictive models, trained on data similar to what venture capitalists use, to project the future value of your shares.
What is AltruBio's equity worth?
The specific value of a private company's equity is not public information and depends on factors like its last funding round valuation and overall performance. You can get a personalized estimate by using a service like Prospect, which analyzes your specific equity grants to project their potential worth.
What is AltruBio's stock ticker symbol?
As a private company, AltruBio is not traded on a public stock exchange and therefore does not have a stock ticker symbol. Ticker symbols are only assigned to companies once they become publicly listed through an event like an Initial Public Offering (IPO).
Can I buy or sell AltruBio stock?
Selling stock in a private company like AltruBio is often possible through secondary markets or tender offers, while buying shares is typically restricted to accredited investors or employees. Platforms like Prospect provide tools to help existing shareholders analyze selling opportunities and optimize their decisions for tax efficiency.
What is the criteria to buy or invest in AltruBio stock?
Investing in a private company is generally limited to accredited investors, venture capital firms, and employees who receive equity as part of their compensation. For those who hold equity, Prospect offers personalized strategies and scenario planning tools to help manage that investment effectively.
